USANA Health ( (USNA) ) has shared an update.
USANA Health Sciences reported a decline in Q3 2024 net sales to $200 million, down from $213 million in Q3 2023, with diluted earnings per share also dropping slightly to $0.56. The company faced challenges in customer acquisition, particularly in its largest market, mainland China, prompting a revised fiscal outlook for 2024. Despite hurdles, USANA continues to innovate with new product launches and strategic initiatives aimed at enhancing customer value. The company remains financially stable with $365 million in cash and no debt.
Learn more about USNA stock on TipRanks’ Stock Analysis page.
